Market Place
Sourcing Support
Zepzelca and Atezolizumab Combo Granted FDA Priority Review
10 Jun 2025 //
PR NEWSWIRE
Roche`s Tecentriq Reduces Recurrence, Deaths for Colon Cancer
07 Jun 2025 //
REUTERS
Roche & Jazz Link Drug Combo to Improve Survival in Ph 3 Trial
04 Jun 2025 //
BIOSPACE
Jazz Zepzelca And Tecentriq Combo Improves Survival In ES-SCLC
02 Jun 2025 //
PR NEWSWIRE
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart
31 May 2025 //
GLOBENEWSWIRE
KAHR Bio to Present Phase 2 Study of DSP107 in Colorectal Cancer
27 May 2025 //
PR NEWSWIRE
ASCO: Roche, Jazz Lung Cancer Win Leaves Room for Improvement
22 May 2025 //
FIERCE PHARMA
Abbisko to Present Ph 2 Study Results of Hepatocellular Carcinoma
12 May 2025 //
PR NEWSWIRE
Phanes Therapeutics Doses First Patient in Peluntamig Study
05 May 2025 //
PR NEWSWIRE
Genprex to Present Acclaim-3 Trial Design at 2025 ASCO Meeting
24 Apr 2025 //
PR NEWSWIRE
Xilio Therapeutics to Present Ph 2 Data for Vilastobart at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
Immune-Onc Doses 1st Patient In IO-108 Ph 1b/2 Liver Study With Roche
27 Feb 2025 //
BUSINESSWIRE
Genprex Doses Patient In Acclaim-3 Phase 2 Study For Lung Cancer
23 Jan 2025 //
PR NEWSWIRE
Xilio Release Ph 2 Data For Vilastobart With Atezolizumab In Cancer
21 Jan 2025 //
GLOBENEWSWIRE
Xilio to Present Ph 2 Data for Vilastobart in Colorectal Cancer
19 Dec 2024 //
GLOBENEWSWIRE
Affimed Reports Update on AFM24/Atezolizumab Combo for NSCLC
17 Dec 2024 //
GLOBENEWSWIRE
Affimed Hosts Investor Call on AFM24 & Atezolizumab in NSCLC
09 Dec 2024 //
GLOBENEWSWIRE
Jazz`s almost-withdrawn lung cancer drug shows life
16 Oct 2024 //
PR NEWSWIRE
Genprex Receives Approval To Advance In Acclaim-3 Trial
15 Oct 2024 //
PR NEWSWIRE
Oncocyte’s DetermaIO Response to Atezolizumab in Ph 2 Trial
08 Oct 2024 //
GLOBENEWSWIRE
Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan
17 Sep 2024 //
FIERCE PHARMA
Exelixis Presents CONTACT-02 Results For Cabozantinib Combo At ESMO
15 Sep 2024 //
BUSINESSWIRE
Ipsen Updates On CONTACT-02 Trial In Prostate Cancer After Final Analysis
15 Sep 2024 //
GLOBENEWSWIRE
Roche`s Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
14 Sep 2024 //
FIERCE PHARMA
FDA Approves Roche`s Subcutaneous Cancer Immunotherapy Tecentriq Hybreza
13 Sep 2024 //
GLOBENEWSWIRE
FDA Approves Genentech`s Subcutaneous Cancer Immunotherapy
12 Sep 2024 //
BUSINESSWIRE
Xilio Therapeutics Announces Q2 2024 Results And Pipeline Updates
08 Aug 2024 //
GLOBENEWSWIRE
Genentech Updates On Phase II/III SKYSCRAPER-06 Study In Lung Cancer
04 Jul 2024 //
BUSINESSWIRE
Tempest Unveils New Data For Amezalpat Showing Six-Month Improvement
20 Jun 2024 //
GLOBENEWSWIRE
Affimed`s AFM24 Combo Shows Durable Responses In Pretreated NSCLC
01 Jun 2024 //
GLOBENEWSWIRE
Affimed Gets Fast Track For AFM24-Atezolizumab In NSCLC
29 May 2024 //
GLOBENEWSWIRE
Affimed Early Efficacy Results: Afm24-102 Egfrwt Nsclc At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Xilio Provides Pipeline Updates, Q1 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
Genprex ExpandsTrial Sites for Acclaim-3 Study with Tecentriq to Treat SCLC
03 Apr 2024 //
PR NEWSWIRE
Gritstone ground down by phase 2 cancer vaccine fail
01 Apr 2024 //
FIERCE BIOTECH
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front
30 Jan 2024 //
FIERCE PHARMA
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
26 Jan 2024 //
ENDPTS
Roche’s Tecentriq SC receives EC approval for cancer treatment
17 Jan 2024 //
PHARMACEUTICAL TECHNOLOGY
Affimed Announces Positive Data for AFM24 in Combination with Atezolizumab
11 Dec 2023 //
GLOBENEWSWIRE
Oncolytics Announces Phase 1/2 Study of Pelareorep Has Met Criteria for Efficacy
09 Nov 2023 //
PR NEWSWIRE
Roche hits FDA delay with subcutaneous Tecentriq
07 Sep 2023 //
FIERCE PHARMA
Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in NSCLC
01 Sep 2023 //
ONCLIVE
England to rollout world-first seven-minute cancer treatment jab
30 Aug 2023 //
REUTERS
Halozyme Announces Approval of Roche`s Tecentriq® SC with ENHANZE
29 Aug 2023 //
PR NEWSWIRE
Roche reports inadvertent disclosure in lung cancer immunotherapy study
24 Aug 2023 //
GLOBENEWSWIRE
Sonnet Announces FDA Acceptance of IND for the SB221 Trial of SON-1010
16 Aug 2023 //
ACCESSWIRE
Tvardi doses first patients in REVERT Liver Cancer trial
23 Jun 2023 //
CLINICAL TRIALS ARENA
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter
23 Jun 2023 //
ONCOLIVE
Sonnet Announces Regulatory Approval for Initiation of a Trial of SON-1010
20 Jun 2023 //
ACCESSWIRE
ASCO: Merck`s Keytruda, Roche`s Tecentriq add to I-O failures
06 Jun 2023 //
FIERCE PHARMA
Patient deaths taint Roche`s landmark adjuvant liver cancer data
16 Apr 2023 //
FIERCE PHARMA
Omega Announces Agreement to Evaluate the Combination of OTX-2002
30 Mar 2023 //
GLOBENEWSWIRE
Roche, Exelixis` Tecentirq-Cabometyx fails a 3rd time
04 Mar 2023 //
FIERCE PHARMA
Exelixis Provides Update on PIII Trial Evaluating Cabozantinib with Atezolizumab
02 Mar 2023 //
BUSINESSWIRE
CARsgen Announces Agreement to Evaluate AB011 with PD-L1 to Treat Gastric Cancer
01 Feb 2023 //
PR NEWSWIRE
Keytruda wins broad adjuvant NSCLC nod to pressure Tecentriq
28 Jan 2023 //
PRESS RELEASE
Roche`s Tecentriq, Avastin combo cuts risk of liver cancer returning
20 Jan 2023 //
BIOPHARMADIVE
Rare cancer drug for young patients approved
03 Jan 2023 //
PHARMAFILE
NIH trial leads to atezolizumab approval for advanced alveolar soft part
30 Dec 2022 //
PHARMABIZ
